Xenomics Inc. (fka XNOM)

[grapeman]

Anesri - Xnom has not proven to be a gem - Dr Faessel use to wrte abou thtem a good bit. Sitll have possiblities so I havng on to some,, but lack buisness peopel to make ti happen.

OOAG may be a gem - They were in court over oi leases for 5-6 years and just had a favorable result. THe CEo Barnett did all kinds of penny stock stuff to stay alive during that time. Now turning into oil company. Go to Yohoo and read current press releases from this week. Retired all preferred shares so R?S needs to be approved by shoreholders etc. Move quick if you like it,,, he will release numbers from one of the wells shortly and he seems like an eager beaver finally out of court after 5-6 years he now can run an oil compnay na d seems like he wants to put out PR about company changes ( into a real company) everyday.

Just oging thoruhg my old ihub boards to see if anything new and came across yours again. Just a tip take you own action.

[ANESRI]

Hi,

Do you follow this gem? There has not been any news. How did you get your info? I have been following this for atleast 2 years. The potential is huge here if things work out as planned.

[grapeman]

Patent issues behind - I think application/ distribution issues finally being addressed.

[grapeman]

Starting to get some take off momentum.
Wonder if this is all about malaria in Africa meetings in Washington / Pres. Bush dancing etc.

[IhubDude]

Has anyone ever set a target here?

[IhubDude]

what ever happened last August to November.Chart looks a little
funny

[cannonball2010]

Xenomcis Takes Aim at Amniocentisis With Transrenal DNA

Like many biotech breakthroughs, this particular technology has its roots in a 20 year old discovery. In 1986, Dr. Samuil Umansky was working for the Russian Health Ministry and doing clinical research on the radiation poisoning from the Chenobyl disaster.

Dr. Umansky discovered that radiation poison could be detected in urine. In order to be in urine, the radiation had to survive the kidney's highly effective cleansing process. The radiation poison was actually carried in the DNA. Until that discovery, the health sciences community never realized DNA could survive the kidneys and be passed out of the body in urine.

Hence the phrase "Transrenal DNA"- this is DNA which has been passed through the kidneys and can be detected and analyzed in urine.



Fast forward to 1996. Dr. Umansky is in the US, and has three patents concerning the use of Transrenal DNA. The three patents cover the applications of Transrenal DNA for use in transplantation, cancer, and early genetic testing of an unborn fetus.

The company, as it exists today, has been operating since last July. Despite being public since that time, XNOM has never made any effort to get its message out to investors. Therefore, you get the first look.

The company sees potential revenue generating applications in four areas for Transrenal DNA;

Cancer Detection
Infectious Disease Detection
Genetic Testing of an Unborn Fetus
Transplantation Monitoring
XNOM has spent the last nine months gathering data in its lab facility in Princeton, NJ. Ten highly qualified scientists work there on a full time basis doing the foundational research.

To date, XNOM has successfully harvested over 300 samples, otherwise known as "data points" in the industry. They have identified alien DNA (DNA not from the mother) in 119 urine samples from pregnant women, and analyzed data points from 200 samples of cancer patients in a study conducted with Thomas Jefferson University.

XNOM is destined to end up on the radar screens of many investors in the coming months. XNOM is preparing to start clinical trials for an FDA Approval of its first application in April. Since this is a non-invasive urine test, XNOM need only demonstrate the product works. They don't have the same stringent requirements you would have with a new drug. Therefore, XNOM anticipates it will only take about 2 years to obtain the FDA Approval. Clinical data will be made available to the public markets thoughout the course of the studies.



XNOM is taking aim at the barbaric "AMNIOCENTESIS" test performed on pregnant women worldwide. In the US alone there are approximately 6.2 million pregnancies each year. Of those, 10% to 15% are considered high risk for genetic diseases such as Downs Syndrome, Sickle Cell Anemia, Tay Sachs, and Huntingtons.

Currently, most pregnant women undergo a three panel test to prescreen prior to amniocentesis. If the doctor and patient decide to move forward, the amniocentesis test is performed.

An eight inch needle is inserted into the pregnant women's abdomen. Barbaric for a simple test. It penetrates the amniotic sack, and a small amount of amniotic fluid is withdrawn. The test is highly invasive and very dangerous. About 1% of tests performed lead to negative complications.

The amniotic fluid contains fetal DNA, which can be tested for genetic diseases.

XNOM expects to begin clinical trials in April for a test which could make amniocentesis obsolete. The test will be designed to replace the three panel test doctors recommend before considering amniocentesis. Most pregnant women who receive medical care in the US take this test.

XNOM's patented technology has the capability of identifying the fetal DNA in the mother's urine. Once identified, the DNA can be tested for genetic diseases.

Down the road XNOM intends to develop cancer and organ transplantation tests using the patented Transrenal DNA. In transplantation the patient has tissue with someone else's DNA. Early rejection can be detected in DNA changes. DNA from tumors can also be detected. Early detection of colon, liver, and pancreatic cancer is also possible with Transrenal DNA.



Today, after the market closed, XNOM announced an exciting development out of its joint venture with the National Institute for Infectious Diseases in Italy known as Lazzaro Spallanzani. XNOMannounced clinical results that demonstrate for the first time the ability to detect tuberculosis DNA in the urine of HIV infected patients. This could lead to the development of tests which provide significant advantages over the current tests.

There is a lot more to cover with this company. The management team led by CEO Randy White is exemplary. Randy White's resume is extraordinary in the biotech industry. Thomas Adams serves on the board- he was the CTO at stock market superstar Hybritech, and the founder and Chairman of Gen Probe, Inc, the leader in blood screening technologies. We'll save that for future editions.

There is not much to say about the trading history of the stock. The little it has traded has been in the $4 range for the last six months. I have absolutely no idea where it will trade tomorrow. It closed today at $2.50. There are 16.5 million shares I&O according to their last SEC filing. This idea is only for long term investors who want to get in on the first look at unique and exciting new biotechnology. If you like the biotech sector, a small position in this stock is a must own for the speculative end of your portfolio.

[cannonball2010]

XNOM the stock to own:

Xenomics Establishes Department of Licensing and Intellectual Property, Hires Veteran Patent Agent David Ladner to Head Unit

Thursday March 24, 4:01 pm ET

Former Bayer and American Cyanamid Executive Will Direct Company's Intellectual Property and Licensing Business

NEW YORK--(BUSINESS WIRE)--March 24, 2005--Xenomics, Inc. (OTCBB:XNOM - News), a developer of next-generation medical DNA technologies, has announced the formation of a Department of Licensing and Patents to manage the growth and licensing business of the Company's expanding intellectual property portfolio. Dr. David Ladner, a patent agent and research scientist with extensive background in the pharmaceutical and chemical industries, has been hired to lead the new unit in the position of Director of Licensing and Intellectual Property.

"The continued expansion of our intellectual property portfolio and the potential for licensing revenues is central to Xenomics' strategic plans for growth and increased shareholder value," said Dr. Randy White, CEO of Xenomics. "As we move from research to commercial product development our intellectual property portfolio has already started to expand in both the U.S. and Europe. Dr. Ladner's appointment as Director of Licensing and Intellectual Property is a key addition to help us manage our growth in this crucial area."

Xenomics is developing and commercializing proprietary gateway DNA testing technology that has the potential to significantly expand the field of molecular diagnostics, currently a $1.5 billion segment of the health care and biotechnology industry. The Company is using its patented Transrenal DNA-based technology platform to develop a number of medical tests for infectious diseases including AIDS and tuberculosis, and for prenatal genetic testing, including gender determination, Rh incompatibility and Down syndrome. Xenomics' breakthrough technology enables detection of DNA using safe, simple and non-invasive urine collection, which offers a number of significant advantages over current techniques that require blood or tissue sampling.

Dr. Ladner, a longtime senior research scientist with extensive experience as a patent agent and specialist in the chemical and pharmaceutical industries, holds a Ph.D. in Organic Chemistry and is currently pursuing an MBA. He was a manager of Intellectual Property at Bayer Pharmaceutical Division for the last five years, where he handled patent filing and prosecution for Chemical Research. He also served as Patent Liaison as well as Research Manager at American Cyanamid Co., for over 20 years, overseeing key aspects of patents and intellectual property. Dr. Ladner holds 22 patents himself, and has published widely in professional journals.

"We are lucky to have someone with David's experience to guide our patent expansion and licensing business," said Dr. White. "His scientific background and technical knowledge of the patent and licensing area is a perfect combination for interaction with our scientific staff."

"I'm excited to bring my experience in patents and licensing to a company with such great potential as Xenomics," said Dr. Ladner. "I believe the company is poised to make extensive and important scientific discoveries, and I look forward to being a part of the team."

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using trans-renal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
Contact:

Xenomics, Inc.
Randy White, 212-297-0808
or
Trilogy Capital Partners, Inc. (Investor Relations)
Paul Karon, 800-342-1467
[e-mail]

Source: Xenomics, Inc